Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04001114
Other study ID # HP-00086422
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 15, 2021
Est. completion date December 2023

Study information

Verified date October 2022
Source University of Maryland, Baltimore
Contact Britta Hahn, Ph.D.
Phone 4104026112
Email bhahn@som.umaryland.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Higher rates and severity of tobacco dependence in people with schizophrenia, as compared with the general population, contribute to the lower life expectancy seen in this population. Dependent tobacco smoking is controlled by how different aspects of cigarette smoking are perceived. There is evidence suggesting that people with schizophrenia differ in how they perceive cigarette smoking, which, if confirmed, would have implications for tailoring treatment interventions for smoking cessation in schizophrenia.


Description:

The aim of the present study is to determine whether tobacco smoking in people with schizophrenia is governed by different aspects and effects of cigarette consumption. Smokers participating in this study either have no psychiatric diagnosis, or a diagnosis of schizophrenia or schizoaffective disorder. Over four study visits, participants will sample and compare different research cigarettes, complete questionnaires and concentration tasks, and smoke one type of research cigarette for eight hours while wearing a nicotine patch. By shaping our understanding of tobacco dependence in schizophrenia, the present project may redirect treatment development toward strategies tailored to the specific vulnerabilities of this population, which is among the most severely affected by its detrimental impact on health and life.


Recruitment information / eligibility

Status Recruiting
Enrollment 90
Est. completion date December 2023
Est. primary completion date June 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Regular smoker of at least 10 cigarettes or cigarillos/day for at least 2 years - For participants with schizophrenia: DSM-5 diagnosis of schizophrenia or schizoaffective disorder - For participants with schizophrenia: Able to give informed consent - For smokers with schizophrenia: No change in psychiatric medication or dosage in the last 4 weeks Exclusion Criteria: - Uncontrolled hypertension (resting systolic BP above 150 or diastolic above 95 mm Hg) - Cardiovascular disease, such as history of myocardial infarction and ischemia, heart failure, angina, severe arrhythmias, or EKG abnormalities - Severe asthma - Chronic obstructive pulmonary disease - Neurological illness, such as stroke, seizure disorder, neurodegenerative disease, or organic brain syndrome - Mental retardation - Alcohol or substance use disorder except nicotine within the last year - Use of benztropine (Cogentin), varenicline (Chantix), bupropion (Wellbutrin, Zyban), or any type of nicotine replacement - Pregnant or lactating - For healthy control smokers: DSM-5 diagnosis of depression, bipolar disorder, ADHD, autism spectrum disorder, anorexia, bulimia nervosa, or any schizophrenia-spectrum disorder - For healthy control smokers: immediate family history of psychosis

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
Sampling Research Cigarettes
Participants sample two research cigarettes, which differ in typical tobacco smoke constituents such as tar, nicotine, carbon monoxide, etc. In the Cigarette Discrimination Session, participants sample both types of cigarettes repeatedly, guess their identity (A or B) with regard to reference cigarettes, and rate their subjective effects. In the Ad Libitum Smoking Session, participants can smoke one of these cigarette types as much or as little as they like for eight hours.

Locations

Country Name City State
United States Maryland Psychiatric Research Center Catonsville Maryland

Sponsors (1)

Lead Sponsor Collaborator
University of Maryland, Baltimore

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in exhaled carbon monoxide The concentration (ppm) of carbon monoxide (CO) in breath is measured by exhalation into a CO breathalyzer at the beginning of the Ad Libitum Smoking Session (baseline), and at the end eight hours later. The change value is obtained by subtracting each participant's baseline value from the end-of-session value. One day (in the Ad Libitum Smoking Session), over an 8-hour time frame.
Primary Cigarette Discrimination Accuracy Participants sample 4 cigarettes of type A and 4 cigarettes of type B in a double-blind manner and indicate for each cigarette if they think it is of type A or B. Two reference trials with cigarette type unblinded will be performed before the first and fifth sample cigarette. For each sampled cigarette, the score is either 1 (correct) or 0 (incorrect). Discrimination accuracy is calculated by averaging the eight scores for each participant. One day (in the Cigarette Discrimination Session), over a 6-hour time frame.
Secondary Change in the number of research cigarettes smoked In the Ad Libitum Smoking Session, participants can smoke as many research cigarettes as they wish. We quantify the number of cigarettes smoked in the first two hours and in the last two hours of the session and calculate the difference score by subtracting the number in the last two hours from that in the first two hours. One day (in the Ad Libitum Smoking Session), over an 8-hour time frame.
Secondary Difference in subjective state composite score The difference in subjective state composite score is derived by transforming each subject's score on the Minnesota Nicotine Withdrawal Scale, the Affect-based Withdrawal Scale, the Questionnaire for Smoking Urges, and the modified Cigarette Evaluation Questionnaire into standard z-scores, calculating the difference between Research Cigarette A and B for each scale, and averaging the absolute values across scales. One day (in the Cigarette Discrimination Session), over a 6-hour time frame.
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A